Which plasma pTau217 assay should I use in clinical practice? Pandora’s box demystified

IF 10.6 1区医学 Q1 CLINICAL NEUROLOGY

Brain Pub Date : 2025-01-09 DOI:10.1093/brain/awaf007

Sofia Toniolo

引用次数: 0

Abstract

This scientific commentary refers to ‘A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests’ by Warmenhoven et al. (https://doi.org/10.1093/brain/awae346) and ‘Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison’ by Pilotto et al. (https://doi.org/10.1093/brain/awae368).

查看原文本刊更多论文

我应该在临床实践中使用哪种血浆pTau217检测？揭开潘多拉魔盒的神秘面纱

这篇科学评论引用了Warmenhoven等人（https://doi.org/10.1093/brain/awae346）的“关键血浆磷酸化tau217生物标志物测试的全面对头比较”和Pilotto等人的“阿尔茨海默病的血浆p-tau217: Lumipulse和ALZpath SIMOA对头比较”（https://doi.org/10.1093/brain/awae368）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain 医学-临床神经学

CiteScore

20.30

自引率

4.10%

发文量

458

审稿时长

3-6 weeks

期刊介绍： Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.